Literature DB >> 21460010

Cutaneous leishmaniasis after travel to Cyprus and successful treatment with miltefosine.

Wolfgang Poeppl1, Julia Walochnik, Tom Pustelnik, Herbert Auer, Gerhard Mooseder.   

Abstract

A patient presenting with an atypical manifestation of cutaneous leishmaniasis after travel to Cyprus was successfully treated with miltefosine. The K26 typing revealed a hitherto undescribed strain of the Leishmania donovani/infantum complex as the causing agent.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21460010      PMCID： PMC3062449          DOI： 10.4269/ajtmh.2011.10-0645

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN： 0002-9637            Impact factor:   2.345


  17 in total

1.  Oral miltefosine to treat new world cutaneous leishmaniasis.

Authors:  Jaime Soto; Julia T Toledo
Journal:  Lancet Infect Dis       Date:  2007-01       Impact factor: 25.071

2.  Leishmania donovani leishmaniasis in Cyprus.

Authors:  Maria Antoniou; Christos Haralambous; Apostolos Mazeris; Francine Pratlong; Jean-Pierre Dedet; Ketty Soteriadou
Journal:  Lancet Infect Dis       Date:  2008-01       Impact factor: 25.071

3.  Cutaneous leishmaniasis: an increasing threat for travellers.

Authors:  S Antinori; E Gianelli; S Calattini; E Longhi; M Gramiccia; M Corbellino
Journal:  Clin Microbiol Infect       Date:  2005-05       Impact factor: 8.067

4.  Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment.

Authors:  Manuel Calvopina; Eduardo A Gomez; Herbert Sindermann; Philip J Cooper; Yoshihisa Hashiguchi
Journal:  Am J Trop Med Hyg       Date:  2006-12       Impact factor: 2.345

Review 5.  Cutaneous leishmaniasis.

Authors:  Richard Reithinger; Jean-Claude Dujardin; Hechmi Louzir; Claude Pirmez; Bruce Alexander; Simon Brooker
Journal:  Lancet Infect Dis       Date:  2007-09       Impact factor: 25.071

Review 6.  Treatment of cutaneous leishmaniasis among travellers.

Authors:  J Blum; P Desjeux; E Schwartz; B Beck; C Hatz
Journal:  J Antimicrob Chemother       Date:  2004-01-16       Impact factor: 5.790

7.  Development of a molecular assay specific for the Leishmania donovani complex that discriminates L. donovani/Leishmania infantum zymodemes: a useful tool for typing MON-1.

Authors:  Christos Haralambous; Maria Antoniou; Francine Pratlong; Jean-Pierre Dedet; Ketty Soteriadou
Journal:  Diagn Microbiol Infect Dis       Date:  2007-09-21       Impact factor: 2.803

Review 8.  Interventions for Old World cutaneous leishmaniasis.

Authors:  Urbà González; Mariona Pinart; Ludovic Reveiz; Jorge Alvar
Journal:  Cochrane Database Syst Rev       Date:  2008-10-08

9.  Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran.

Authors:  M Mohebali; A Fotouhi; B Hooshmand; Z Zarei; B Akhoundi; A Rahnema; A R Razaghian; M J Kabir; A Nadim
Journal:  Acta Trop       Date:  2007-05-18       Impact factor: 3.112

Review 10.  Spread of vector-borne diseases and neglect of Leishmaniasis, Europe.

Authors:  Jean-Claude Dujardin; Lenea Campino; Carmen Cañavate; Jean-Pierre Dedet; Luigi Gradoni; Ketty Soteriadou; Apostolos Mazeris; Yusuf Ozbel; Marleen Boelaert
Journal:  Emerg Infect Dis       Date:  2008-07       Impact factor: 6.883
View more
  2 in total

Review 1.  Non-Endemic Leishmaniases Reported Globally in Humans between 2000 and 2021-A Comprehensive Review.

Authors:  Rafael Rocha; André Pereira; Carla Maia
Journal:  Pathogens       Date:  2022-08-16

2.  Miltefosine for Mucosal and Complicated Cutaneous Old World Leishmaniasis: A Case Series and Review of the Literature.

Authors:  Vincent Mosimann; Claudia Blazek; Heini Grob; Matthew Chaney; Andreas Neumayr; Johannes Blum
Journal:  Open Forum Infect Dis       Date:  2016-02-01       Impact factor: 3.835
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.